Last reviewed · How we verify
Indion (PHENINDIONE)
At a glance
| Generic name | PHENINDIONE |
|---|---|
| Sponsor | Sanofi |
| Drug class | phenindione |
| Target | Prothrombin, Vitamin K epoxide reductase complex subunit 1, Arachidonate 5-lipoxygenase |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
| First approval | 1982 |
Approved indications
Common side effects
Key clinical trials
- Registry on Augmented Antithrombotic Treatment Regimens for Patients With Arterial Thrombotic APS
- Start or STop Anticoagulants Randomised Trial (SoSTART) (PHASE3)
- Burden of Ischemic Stroke and Intake of Oral Anticoagulants in Patients With Atrial Fibrillation in the UK Primary Care
- Safety And Efficacy of Low Dose Oral Anticoagulants And Aspirin Therapy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Indion CI brief — competitive landscape report
- Indion updates RSS · CI watch RSS
- Sanofi portfolio CI